Swedish biopharma Calliditas Therapeutics (Nasdaq: CALT) continues to press for full approval of Nefecon/Tarpeyo (budesonide) delayed release capsules/Kinpeygo.
The delayed-release formula won accelerated approved in the USA for people with the rare condition IgA nephropathy (IgAN) at the end of 2021. Also known as Berger’s disease, IgAN is as progressive and chronic autoimmune disease that attacks the kidneys.
"A differentiated and disease-modifying treatment alternative"This approval was based on a reduction in proteinuria, with the US Food and Drug Administration (FDA) reserving a full nod pending proof the therapy can slow kidney function decline.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze